Novartis announced recently that data from a new analysis demonstrating that fewer heart failure patients with reduced ejection fraction (HFrEF) treated with Entresto™ (sacubitril/valsartan) tablets were readmitted to the hospital for heart failure or for any cause within 30 days of discharge from a heart failure hospitalization, compared to patients treated with enalapril.1 This post-hoc analysis of PARADIGM-HF data, the largest clinical trial ever conducted in heart failure,7 was presented at the American Heart Association Scientific Sessions 2015.

The analysis compared numbers and rates of 30-day readmissions after discharge from heart failure hospitalizations between patients who were randomized to treatment with Entresto and those who received enalapril. The primary outcome analyzed was investigator-reported readmissions for any cause within 30 days of discharge from a heart failure hospitalization.

For full results and the rest of the press release, please go here.